From Medscape Dermatology

The 3rd Annual Revolutionizing Atopic Dermatitis (RAD) Conference

December 11 - 13, 2021; Virtual

December 11 - 13, 2021 Virtual

RAD 2021 Increased Dosing Can Benefit Overweight Patients With Psoriasis 'Weight may have an impact on pharmacokinetics and, therefore, on the clinical outcome of biologic treatment for psoriasis,' the authors commented.
Medscape Medical News, January 26, 2022
RAD 2021 AD Severity Linked to More Frequent Bathing, Not Duration Current guidelines on bathing frequency and duration among AD patients lack consensus, are limited, and are largely based on studies of pediatric populations.
Medscape Medical News, December 15, 2021
RAD 2021 Abrocitinib Efficacy Dose-Dependent, Similar Across AD Age Groups As for adverse events, nausea was more frequent in patients aged 12-17 and aged 18-40 years than it was for those age 51 or older.
Medscape Medical News, December 14, 2021

Baseline Body Surface Area May Drive Optimal Baricitinib Response Patients with moderate to severe atopic dermatitis affecting between 10% and 50% of their body surface area account for the majority of those responders to baricitinib 2 mg.
Medscape Medical News, Jan 11, 2021
Curbing Itch Intensity, Frequency in Children With Severe Eczema "Severe AD is complex, highly symptomatic, multidimensional condition characterized by an intense pruritus that negatively impacts a patient's life," said Gil Yosipovitch, MD.
Medscape Medical News, Jan 08, 2021
Severe Atopic Dermatitis Often Puts a Dent in Quality of Life In his role as head of the division of pediatric behavioral health at National Jewish Health, Bruce Bender, PhD, helps kids and adults navigate the adverse effects of severe AD on their quality of life.
Medscape Medical News, Mar 04, 2021

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resources